CompletedNot Applicable

The Fluoroless-CSP Trial Using Electroanatomic Mapping

United States2 participantsStarted 2020-10-26

Plain-language summary

The goal of this study is to assess the feasibility, accuracy and safety of performing fluoroless (or low fluoro) conduction system pacing utilizing electro-anatomic mapping (EAM) with the CARTO 3 mapping system (Biosense Webster Inc, Irvine, CA) in comparison to a group of patients undergoing conventional conduction system pacing (CSP) Implants.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 years * Indication for Permanent Pacemaker implantation or implantation of Cardiac Resynchronization Therapy Device Exclusion Criteria: * Existing cardiac device including Pacemaker or Cardiac Resynchronization Therapy device * Inability of patient capacity to provide consent for themselves either due to medical or psychiatric comorbidity * Pregnancy * Difficulty with follow-up

What they're measuring

Success of achieving CSP

Timeframe: Intra-procedure

Trial details

NCT IDNCT03903107

SponsorRush University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-01

View on ClinicalTrials.gov More Sinus Node Dysfunction trials